LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

AZN

176.29

-0.5%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

AZN

176.29

-0.5%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

AZN

176.29

-0.5%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

AZN

176.29

-0.5%↓

LLY

1,080.21

+1.73%↑

JNJ

223.5

+0.31%↑

UNH

377.97

+0.23%↑

MRK

114.86

-0.95%↓

AZN

176.29

-0.5%↓

Inicio・Lista de Acciones・AbbVie Inc

AbbVie Inc

Cerrado

SectorSanidad

217.16 0.73

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

212.83

Máximo

219.47

Métricas clave
By Trading Economics
Ingresos	-1.1B 697M
Ventas	-1.6B 15B
P/B Media del Sector	104.378 49.888
BPA	2.65
Rentabilidad por dividendo	3.1
Margen de beneficios	4.646
Empleados	57,000
EBITDA	-1.7B 3.7B

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+19.86% upside

Dividendos
By Dow Jones
Rentabilidad por dividendo Media del Sector	3.10% 2.38%
Próximas Ganancias	30 jul 2026
Fecha Próximo Dividendo	14 ago 2026
Próxima Fecha de Ex Dividendo	14 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	27B 376B
Apertura anterior	216.43
Cierre anterior	217.16

Noticias sobre sentimiento de mercado

By Acuity

48%

52%

141 / 344 Clasificación en Healthcare

AbbVie Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

29 abr 2026, 12:38 UTC

Ganancias

AbbVie Raises Fiscal Year Guidance on Immunology, Neuroscience Growth

4 feb 2026, 13:20 UTC

Ganancias

AbbVie 4Q Revenue Rises on Immunology Growth

29 abr 2026, 12:41 UTC

Ganancias

AbbVie Beats Earnings Estimates, Boosts 2026 Outlook. What It Means for the Stock. -- Barrons.com

29 abr 2026, 12:23 UTC

Ganancias

AbbVie Raises FY Guidance on Immunology, Neuroscience Growth

29 abr 2026, 11:50 UTC

Ganancias

AbbVie Raising Adjusted EPS Guidance for FY26 >ABBV

29 abr 2026, 11:49 UTC

Ganancias

AbbVie 1Q Global Humira Rev $688 M >ABBV

29 abr 2026, 11:48 UTC

Ganancias

AbbVie 1Q Global Rinvoq Rev $2.119 B >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Global Net Rev From Oncology Portfolio $1.63B >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Global Skyrizi Rev $4.48B >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Global IMBRUVICA Rev $556M >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q EPS 39c >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Net $695M >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q International HUMIRA Rev $331M >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Rev $15B >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q Adj EPS $2.65 >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie 1Q U.S. HUMIRA Rev $357M >ABBV

29 abr 2026, 11:47 UTC

Ganancias

AbbVie Sees FY Adj EPS $14.08-Adj EPS $14.28 >ABBV

4 feb 2026, 19:38 UTC

Ganancias

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 16:19 UTC

Ganancias

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 15:18 UTC

Ganancias

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 13:18 UTC

Ganancias

AbbVie Earnings Beat Wall Street Expectations. The Stock Is Falling Anyway. -- Barrons.com

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q U.S. HUMIRA Rev $897M >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Rev $16.62B >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Global IMBRUVICA Rev $671M >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Global Skyrizi Rev $5.01B >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Net $1.82B >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Adj EPS $2.71 >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.66B >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie 4Q International HUMIRA Rev $349M >ABBV

4 feb 2026, 12:48 UTC

Ganancias

AbbVie Sees FY Adj EPS $14.37-Adj EPS $14.57 >ABBV

Comparación entre iguales

Cambio de precio

AbbVie Inc previsión

Precio Objetivo

By TipRanks

19.86% repunte

Estimación a 12 Meses

Media 255.22 USD 19.86%

Máximo 298 USD

Mínimo 203 USD

De acuerdo con 20 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para AbbVie Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

20 ratings

Comprar

Mantener

Vender

De acuerdo con 20 analistas que ofrecen calificaciones bursátiles a para AbbVie Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

141 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.